Your session is about to expire
← Back to Search
Pembrolizumab + Radiation for Mesothelioma
Study Summary
This trial is testing the safety of combining two drugs to treat mesothelioma. The goal is to find the highest dose of one drug that causes few side effects when combined with the other drug. If the combination is effective, it will be tested on more people in the future.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious infections, other cancers, or major illnesses.I agree to use contraception for the duration of the treatment and up to 150 days after, if required.I have another cancer that hasn't needed treatment in the last 2 years.I am not pregnant or breastfeeding and will follow birth control advice for 4 months during and after treatment.My cancer is too large in a specific area to allow for certain treatments.I have a history of HIV, Hepatitis B, active Hepatitis C, or active TB.My cancer has spread to my brain or its coverings.I have not received a live vaccine in the last 30 days.My doctor says my lung condition can't be treated with surgery.I can carry out all my usual activities without help.I have been recently diagnosed with mesothelioma.I am fully active or can carry out light work.My organs are functioning well according to the specified criteria.I haven't taken certain medications in the last 4 weeks or still have side effects.I have an immune system disorder or have been taking more than 10 mg of steroids daily.I have had at least one treatment for my condition before.I have had pneumonitis treated with steroids or have it now.I have not needed treatment for an autoimmune disease in the last 2 years.I do not have any health issues that could affect the study's results.I am 18 years or older and have given my consent.My cancer outside the lung on the same side has been stable for 6 months after treatment.I have had radiation therapy or treatment inside my chest area before.I have been diagnosed with cancer of the lung lining.I had major surgery less than 4 weeks before starting pembrolizumab.
- Group 1: Participants with malignant pleural mesothelioma (MPM)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical issues does IMPRINT have the potential to ameliorate?
"IMPRINT may be utilized to manage malignant neoplasms, as well as unrelenting melanomas, microsatellite instability high diseases, and ailments that have advanced despite prior chemotherapy."
On what scale is this clinical investigation being conducted?
"Affirmative. Information found on clinicaltrials.gov suggests that the trial, which was initially posted on August 10th 2021, is still searching for participants to enroll. 24 patients are needed from 7 distinct medical centres."
Are there any Canadian locations currently offering this research initiative?
"The current clinical trial is taking place across 7 different sites, 4 of which are in Harrison, Rockville Centre and Basking Ridge. Participants may choose the closest location to them to lessen travel demands."
Are there further investigations being conducted with IMPRINT?
"IMPRINT's initial research began in 2010 at City of Hope. To this day, there are 251 concluded studies and 961 ongoing trials, the majority being held in Harrison, New york."
Is enrollment still open for participation in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this medical study – which was first published on August 10th 2021– is still recruiting patients. 24 individuals are required across 7 different trial sites."
Has the IMPRINT treatment been cleared for public use by federal regulators?
"In the estimation of our team at Power, IMPRINT has been judged to possess a level 1 safety rating; due to it being in Phase 1 trials and having limited supporting evidence as regards efficacy."
Share this study with friends
Copy Link
Messenger